The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial.
 
Matteo Lambertini
Consulting or Advisory Role - AstraZeneca; Exact Sciences; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche; Seagen
Speakers' Bureau - Ipsen; Knight Therapeutics; Libbs; Lilly; Novartis; Pfizer; Roche; Sandoz; Takeda
 
Marcello Ceppi
No Relationships to Disclose
 
Richard Anderson
Honoraria - IBSA; Merck
Consulting or Advisory Role - NeRRe Therapeutics; Roche; Sojournix
Research Funding - Roche
 
David A. Cameron
Consulting or Advisory Role - Clarity Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Novartis (Inst); Oncolytics (Inst); Pfizer (Inst); Prima BioMed (Inst); Puma Biotechnology (Inst); Research Triangle Institute RTI Health Solutions (Inst); Roche (Inst); Roche (Inst); Samsung Bioepis (Inst); Sanofi (Inst); Seagen (Inst); Synthon (Inst); Zymeworks (Inst); Zymeworks (Inst)
Research Funding - AstraZeneca (Inst); Novartis (Inst); Roche (Inst)
 
Sarra El-Abed
Employment - argenx (I); Astellas Pharma (I)
Research Funding - Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Yingbo Wang
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Christophe Lecocq
No Relationships to Disclose
 
Paolo Nuciforo
Honoraria - Bayer; MSD Oncology; Novartis
Consulting or Advisory Role - Bayer; MSD Oncology
Travel, Accommodations, Expenses - Novartis
 
Rebecca Rolyance
Leadership - Google health (I)
Honoraria - Daiichi Sankyo Europe GmbH; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca
Consulting or Advisory Role - Daiichi Sankyo Europe GmbH; Daiichi Sankyo/Astra Zeneca; Iqvia; Lilly
Travel, Accommodations, Expenses - BMS; Daiichi Sankyo Europe GmbH; Daiichi Sankyo Europe GmbH; Roche/Genentech
 
Lajos Pusztai
Honoraria - Athenex; bioTheranostics; natera; OncoCyte
Consulting or Advisory Role - Almac Diagnostics; AstraZeneca; Bristol Myers Squibb; Clovis Oncology; Eisai; H3 Biomedicine; Immunomedics; Merck; Novartis; Pfizer; Roche/Genentech; Seagen; Syndax
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca
(OPTIONAL) Uncompensated Relationships - Foundation Medicine; NanoString Technologies
 
Joohyuk Sohn
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
Other Relationship - Roche
 
Luca Arecco
No Relationships to Disclose
 
Lucia Del Mastro
Honoraria - Lilly; MSD Oncology; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Exact Sciences; Genomic Health; Gilead Sciences; Ipsen; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Travel, Accommodations, Expenses - Celgene; Pfizer; Roche
 
Ann H. Partridge
Patents, Royalties, Other Intellectual Property - I receive small royalty payments for co-authoring the breast cancer survivorship section of UpToDate
 
Cristina Saura
Consulting or Advisory Role - AstraZeneca; Ax's Consulting; Byondis; Daiichi Sankyo; Eisai; Exact Sciences; Exeter Pharmaceuticals; ISSECAM; MediTech; Merck Sharp & Dohme; Novartis; Pfizer; Philips Healthcare; Pierre Fabre; Pint Pharma; Puma Biotechnology; Roche; Roche; Sanofi/Aventis; Seagen; Zymeworks
Research Funding - Aragon Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim España (Inst); Bristol-Myers Squibb (BMS) (Inst); Cytomx Therapeutics (Inst); Daiichi Sankyo (Inst); Genentech (Inst); German Breast Group (Inst); GlaxoSmithKline (Inst); InnoUp (Inst); International Breast Cancer Study Group (Inst); Lilly (Inst); Macrogenics (Inst); MedSIR (Inst); Menarini (Inst); Merus (Inst); Millennium (Inst); Millennium (Inst); Novartis Farmacéutica (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genomic Health; Novartis; Pfizer; Puma Biotechnology; Roche
 
Michael Untch
Honoraria - Agendia (Inst); Amgen (Inst); Art tempi (Inst); AstraZeneca (Inst); Daiji Sankyo (Inst); Eisai Europe (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst); Sanofi (Inst); Seagen (Inst)
Consulting or Advisory Role - Agendia (Inst); Amgen (Inst); Art tempi (Inst); AstraZeneca (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Molecular Health (Inst); MSD Oncology (Inst); Mylan (Inst); Myriad Genetics (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst); Sanofi Aventis GmbH (Inst)
 
Martine J. Piccart-Gebhart
Consulting or Advisory Role - AstraZeneca; Camel-IDS; Frame Therapeutics; Immunomedics; Immutep; Lilly; Menarini; MSD; NBE Therapeutics; Novartis; Odonate Therapeutics; Pfizer; Roche/Genentech; Seagen; Seagen
Research Funding - AstraZeneca (Inst); Immunomedics/Gilead (Inst); Lilly (Inst); Menarini (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Roche/Genentech (Inst); Servier (Inst); Synthon (Inst)
Other Relationship - EU Cancer Mission Board; Oncolytics
 
Serena Di Cosimo
No Relationships to Disclose
 
Evandro de Azambuja
Honoraria - Libbs (Inst); Novartis/Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech; Seagen; Zodiac Pharma
Consulting or Advisory Role - Libbs; Novartis; Pierre Fabre; Roche/Genentech
Research Funding - AstraZeneca (Inst); GlaxoSmithKline/Novartis (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Roche/Genentech
 
Isabelle Demeestere
Consulting or Advisory Role - Roche
Research Funding - Ferring (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Ferring